Biohaven (NYSE:BHVN) is up 2.9% postmarket after reporting that its migraine medicine rimegepant registered a meaningfully positive outcome in a Phase 3 trial.
Rimegepant is a small molecule calcitonin gene-related peptide receptor antagonist for acute treatment of migraine.
Compared to a placebo, patients treated with one 75 mg dose “experienced superior, rapid pain freedom and freedom from the most bothersome migraine-associated symptom,” the company says.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.